Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Sulfabenzamide+sulfacetamide+sulfathiazole 3.7%/2.86%/3.42% vaginal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
|
Product containing sulfabenzamide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
|
Sulfabenzamide + sulfacetamide + sulfathiazole 184mg/143.75mg/172.5mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
|
Sulfabenzamide + sulfacetamide + sulfathiazole 3.7%ww/2.86%ww/3.42%ww cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
|
Product containing sulfabenzamide and sulfacetamide and sulfathiazole (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |
Sulfabenzamide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |
Sulfabenzamide and sulfacetamide and sulfathiazole only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
2 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
2 |
Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
2 |
Sulfabenzamide 37 mg/mL and sulfacetamide sodium 28.6 mg/mL and sulfathiazole 34.2 mg/mL vaginal cream |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
2 |
Sulfabenzamide- and sulfacetamide- and sulfathiazole-containing product in vaginal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |
Sulfabenzamide and sulfacetamide and sulfathiazole only product in vaginal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sulfabenzamide (substance) |
Inferred relationship |
Some |
1 |